Tafalgie Therapeutics,
Research for health & well-being

Innovative polypeptides for preventing & treating pain.

Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation : a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals.

our ambitions & goal ?

In the context of the current opioid crisis, we aim to become the key player of reference in the pain field, through the design and proposition of new active pharmaceutical ingredients based on the development of first-in-class polypetides derived from TAFA4 and its constituent peptides. At Tafalgie Therapeutics, we aim to develop more effective, better-tolerated, non-addictive, long-term treatments to relieve acute pain, whether mild, moderate or severe, and to prevent chronic pain, and to delivery these treatments to patients. In the medium term, we aim to form partnership agreements with major pharmaceutical companies or specialist international distributors capable of bringing products based on TAFA4 technology to the market.

Project chronology
& history

Tafalgie Therapeutics will build on more than ten years of promising scientific research in France

APPROaCH & context

Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein that modulates the transmission of pain information to the brain.

Pipeline

Tafalgie Therapeutics has developed and identified other new drug candidates.

AN URGENT GLOBAL NEED TO DEVELOP NEW ANALGESICS

Millions

surgical interventions are performed annually

0 %

patients

undergoing surgery experience pain.

Millions

people in Europe suffer from chronic pain.

0 %

patients

do not receive appropriate treatment for their pain.

OUR TEAM OF EXPERTS

Tafalgie Therapeutics has formed a scientific committee and a supervisory board to assist its management team and the founding partners.

The Tafalgie Therapeutics team

At Tafalgie Therapeutics, we have built a world-class team of scientists, engineers, legal and regulatory experts, financiers, and operational managers.

Find out more

aziz moqrich

CSO

Specialist of the peripheral nervous system
Publication in International Journal

Eric schettini

President

Investor Biotech Entrepreneur
Successful IPOs
25 years experience

laurent labatut

Chairman of board

Chemical Industry
Strategic positions in Marketing
Scale up

stephane gaillard

General Manager

Pain research
Mice Models Characterization
Production

olivier blin

Chairman of the COMEX

Professor of clinical pharmacology (AMU)

Past positions : Regulatory Industrial

LATEST NEWS

Tafalgie Therapeutics is a member of two French networks dedicated to healthcare innovation. Discovered :

“Pain is considered to be the root cause of almost two thirds of medical consultations. For this reason, it is the subject of many studies, both fundamental and clinical. Active research on this subject IS absolutely essential to improve our understanding of the mechanisms involved in pain and for the development of new treatments.”

Site Inserm

Aziz Moqrich explains to Thierry Lhermitte (France Inter) how pain is modulated in the human body.